Cross-border health deals under EU FDI screening: a practical map

Any serious conversation about moving Hong Kong capital into European health innovation has to begin with foreign direct investment screening. Investors who treat it as an afterthought get surprised late and expensively. We treat it as a design input from day one.

The landscape has tightened, and it is still moving. The EU's screening framework, built on Regulation (EU) 2019/452, is being meaningfully strengthened: in December 2025 the Council and Parliament reached political agreement on a revised regime that requires every member state to operate a screening mechanism with a common minimum scope, and explicitly captures investments routed through EU subsidiaries. Final decisions remain with national authorities, but the direction of travel is unmistakable — more harmonisation, more mandatory filings, more scrutiny.

For health and life science specifically, this matters more than for most sectors. Biotechnology now sits squarely on the sensitive-sector lists, alongside other critical technologies. Access to patient health data draws particular attention, and the availability of critical medicines and the protection of intellectual property are explicit assessment factors. In other words, the exact qualities that make a Nordic health company attractive are also the qualities that invite review.

None of this makes cross-border health investment impossible. It makes structuring decisive. In practice that means a few disciplines. Understand where the genuine sensitivity lies — patient data, critical-medicine supply, dual-use applications — and be deliberate about exposure to it. Be honest about the difference between a minority growth investment and a controlling stake, because thresholds and obligations differ. Build ownership and governance that can survive a regulator reading them closely, on both sides of the bridge. And engage early rather than presenting authorities with a structure that looks designed to avoid them.

This is why we say the fund is built where most cross-border strategies break. A bridge that ignores the regulatory engineering beneath it is not a bridge; it is a risk waiting to be discovered. Designing for screening from the outset is slower and more demanding — and it is precisely what makes the structure something a Nordic limited partner can trust.

*Regulatory positions described here reflect the framework as we understand it at the time of writing and are not legal advice; specific transactions require qualified counsel.*